Introduction
Biliary tract carcinoma (BTCa) is still difficult to detect at an early stage, resulting in a poor prognosis, 1 despite recent progress in various imaging modalities, such as endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasonography (EUS), computed tomography (CT), and magnetic resonance imaging (MRI). Cytological examinations of bile have been conducted to diagnose BTCa qualitatively. Although some skillful cytologists have reported relatively high positive rates in BTCa, the accuracy of bile cytology for the diagnosis of BTCa has been limited, due to cell injury and degradation induced by various proteases present in bile juice. 2, 3 Thus, analyses of cancer-related genes in bile for the specific diagnosis of BTCa have been anticipated. Only a few researchers have tried to analyze p53 or K-ras mutations in bile from patients with biliary malignancy, 4, 5 but the usefulness of p53 or K-ras genetic analyses seems to be limited because of insufficient sensitivity or false positivity.
Recently, Yamashita et al. 6 and the authors 7 of this article found that the incidence of K-ras mutations in pancreatic cancer (PCa) was higher in the supernatant (Sup) than in the sediment (Sed) of pancreatic juice (PJ), suggesting the usefulness of Sup from body fluids for genetic analysis.
To improve the molecular diagnosis of BTCa, we analyzed p53 and K-ras mutations in DNA extracted not only from the Sed but also from the Sup of bile samples and evaluated the clinical usefulness of genetic analyses in comparison with bile cytology for the diagnosis of BTCa.
Background. The sensitivity of bile cytology for the diagnosis of biliary tract carcinoma (BTCa) is still low. In addition, the incidence of detection of genetic mutations in the bile of BTCa is not satisfactory yet. To improve the molecular diagnosis of BTCa, we analyzed p53 and K-ras mutations in DNA extracted from not only the sediment but the supernatant of bile samples. Methods. Polymerase chain reaction-single-strand conformation polymorphism and direct sequencing were used for analyses of p53 mutations in exons 5 through 8. K-ras mutations at codon 12 were examined by mutant allele-specific amplification. Results. In bile supernatant from patients with BTCa, p53 and K-ras mutations were detected in 50.0% (15/30) and 56.7% (17/30) of cases, respectively. The incidence of p53 and K-ras mutations in the sediment was 33.3% and 43.3%, respectively. When a combination assay with both genes was used, molecular abnormalities were detected in 80.0% of cases, including 3 in which p53 alone was positive. In addition, either p53 or K-ras mutations were detected in 12 of 15 (80.0%) cases of BTCa in which the cytologic diagnoses were negative. p53 mutations were detected in neither supernatant nor sediment in 20 patients with cholelithiasis, although the incidence of K-ras mutations in the sediment was 20%. Conclusions. The incidence of p53 and K-ras mutations is higher in the supernatant than in the sediment, and simultaneous analyses of p53 and K-ras in the two bile fractions could enhance the genetic diagnosis of BTCa. Notably, the specificity of p53 mutations for cancer was very high in bile samples, and the sensitivity was also relatively high.
Methods

Patients and bile samples
According to the guidelines of the Ethics Committee on Human Investigation of our hospital, written informed consent was obtained from all patients in the study, who were diagnosed and treated at the Department of Internal Medicine at Kanazawa University Cancer Research Institute Hospital and affiliated hospitals between June 1999 and July 2001. Bile samples were obtained from 30 patients with BTCa (17 men and 13 women; median age, 68.7 years; range, 34-86 years; 8 gallbladder carcinomas, 11 proximal bile duct carcinomas [i.e., intrahepatic bile duct carcinoma and perihilar bile duct carcinoma], and 11 distal bile duct carcinomas), 3 patients with malignant biliary strictures (due to hepatocellular carcinoma and lymph node metastasis from gastric cancer or pulmonary cancer) (Table 1) , and 20 patients with cholelithiasis. In the patients with BTCa, surgery was performed, and a histologic diagnosis was obtained in 8 patients. Of these, tissue samples were available for genetic analyses in patients 7 and 17 (Table  1) with BTCa. Other carcinoma patients had inoperable advanced disease, and diagnoses were made by the typical results indicating the presence of BTCa with several imaging modalities such as ultrasonography, CT, MRI, ERCP, and EUS combined with laboratory examinations. Proximal and distal bile duct carcinomas were classified according to a previous report. 8 In 3 of the 11 Biliary tract cancer  1  59  F  DBD  IV  V  Exon 5  Exon 5  132  AAGAEAGG  TGT  TGT  2  84  M  DBD  III  I  Exon 5  Exon 5  149  TCCAEACC  AGT  AGT  3  87  F  DBD  III  ND  Exon 6  Exon 6  202  CGTAECAT  AGT  AGT  4  84  F  GB  IV  V  Exon 6  Exon 6  221  GAGAECAG  -GAT  5  79  F  DBD  III 
Human PCa cell lines
To investigate the limit of detection of the p53 mutant band by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and enriched-SSCP (E-SSCP) analysis, we used two human PCa lines, Panc-1 and BxPC-3. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% calf serum at 37°C, in 5% CO 2 .
Cytological examination of bile juice
Smears of cell pellets were made on glass slides, fixed in 95% ethyl alcohol, and stained by the Papanicolaou technique. Cells were diagnosed cytologically as class I, normal; class II, probably normal; class III, doubtful (atypical cells); class IV, probably cancer; and class V, definitely cancer.
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DNA extraction
Approximate 30-ml samples of fresh bile were collected and separated into Sup and Sed by centrifugation at 1200 rpm for 5 min. DNA was extracted from the Sup and Sed of bile by using phenol/chloroform, as described previously. 11 In regard to patients 7 and 17 with BTCa (listed in Table 1 ), the extraction of DNA from microdissected BTCa tissues was performed by the same method.
Nonradioactive SSCP, E-SSCP, and sequence analyses for p53 mutations
PCR primers were designed for the flanking site of exons 5, 6, 7, and 8 of the p53 gene, in which most of the point mutations have been reported previously. 12 The sequences of the primers were as follows: exon 5 sense, TTC CTC TTC CTG CAG TAC TC; antisense, CAG CTG CTC ACC ATC GCT AT; exon 6 sense, CAC TGA TTG CTC TTA GGT CT; antisense, AGT TGC AAA CCA GAC CTC AG; exon 7 sense, GTG TTA TCT CCT AGG TTG GC; antisense, CAA GTG GCT CCT GAC CTG GA; exon 8 sense, CCT ATC CTG AGT AGT GGT AA; and antisense, TCC TGC TTG CTT ACC TCG CT. PCR product sizes were 210 base pairs (bp) for exon 5, 144 bp for exon 6, 144 bp for exon 7, and 165 bp for exon 8. PCR was performed with AmpliTaq Gold polymerase (Perkin-Elmer Cetus, Foster, NJ, USA; 1.5 U), template DNA (100 ng), and primer (10 pmol), denatured at 95°C for 1 min, annealed at 52°C for 1 min, and extended at 74°C for 1 min, for 45 cycles. Subsequently, SSCP was performed. After denaturing with 95% formamide for 15 min at 80°C, electrophoresis was performed at 6°C and 150 V for 14-18 h, using a 15% homogeneous polyacrylamide gel (Atto, Tokyo, Japan). Silver staining (silver staining kit 2D; Daiichi, Tokyo, Japan) was used for visualization of the bands.
E-SSCP is based on the observation that the vast majority of mutated bands migrate close to the wildtype bands in conventional SSCP analyses. 13 When mutant bands could not be seen on conventional SSCP, an area of 1 cm above and below the wild-type singlestrand bands, where a region containing mutant alleles is most likely to exist was cut with a sterile scalpel, and the DNA contained in the gel was resuspended in twice distilled water. The DNA samples, presumed to be enriched with mutated alleles, were then subjected to a second PCR-SSCP assay, performed under the same conditions as the first, to detect mutations. E-SSCP was tried in all cases in which the mutant bands of p53 were not visible on conventional SSCP.
With regard to sequence analysis, cycle sequence reaction was carried out with template DNA (15 ng), the primers (2.5 pmol) used in PCR corresponding to each exon, and BigDye Terminator Cycle Sequence Reaction agent (8 µl; Perkin-Elmer Cetus), denatured at 96°C for 30 s, annealed at 50°C for 15 s, and extended at 60°C for 4 min, for 25 cycles in the thermal cycler. Then, reaction products were purified on a Centrisep (PerkinElmer Cetus) spin column, and sequence analyses were performed with an ABI PRISM 310 Genetic Analyzer (Perkin-Elmer Cetus).
Mutant allele-specific amplification (MASA) for K-ras mutations at codon 12
Mutations of K-ras codon 12 were analyzed according to a modified MASA method reported by Takeda et al., 14 as shown in our previous publications. 7, 15 The se-quences of primers were as follows: sense, ACT TGT GGT AGT TGG AGC TA (AGT), ACT TGT GGT AGT TGG AGC TC (CGT), ACT TGT GGT AGT TGG AGC TT (TGT), CTT GTG GTA GTT GGA GCT GA (GAT), CTT GTG GTA GTT GGA GCT GC (GCT), CTT GTG GTA GTT GGA GCT GT (GTT); antisense, CTC ATG AAA ATG GTC AGA GAA ACC. In brief, the 3Ј-terminal base of the sense primer was set to correspond to each of the three possible mutant bases of the first base of K-ras codon 12, and these three mutant sense primers were mixed and named Set 1. In the same manner, the three mutant sense primers for the second base of K-ras codon 12 were mixed and named Set 2. PCR was performed with AmpliTaq Gold polymerase (1.5 U; Perkin-Elmer Cetus), template DNA (100 ng), primer (10 pmol), and MgCl 2 (1.0 mM), with denaturing at 95°C for 30 s, annealing at 63.5°C for 60 s, and extension at 70°C for 90 s, for 40 cycles. Then, electrophoresis with 2% NuSieve agarose gel (FMC Bio-Products, Rockland, MD, USA) was performed, followed by ethidium bromide (0.5 µg/ ml) or SYBR Gold (Molecular Probes, Eugene, OR, USA) staining of the gel. When a specific single band of PCR product was visualized under ultraviolet illumination, as shown in Fig. 1A , K-ras mutations were judged as being present for Set 1 or Set 2. Each PCR product was 179 bp for Set 1 and 178 bp for Set 2. Next, PCR was performed again under the same conditions with each mutant primer instead of Set 1 and Set 2. Finally, if the specific mutant band appeared, the types of K-ras mutations were identified, as shown in Fig. 1B .
Statistical analysis
Statistical evaluation was performed by using the 2 test to assess the correlation between the incidence of p53 or K-ras mutations and the location of BTCa. A P value of less than 0.05 was judged as significant.
Results
Sensitivity of SSCP, E-SSCP, and MASA
To verify the sensitivity of SSCP for the analyses of p53 mutations, DNA samples from the cell line Panc-1 (mutant in exon 8) were mixed with the wild-type DNA from cell line BxPC-3 (wild-type in exon 8) at constant ratios (relative to the wild-type DNA) of 50% to 0.01%, with total DNA content kept constant, and then the mixtures were used as the templates for PCR. The PCR products were subjected to nonradioactive SSCP. The mutant band was visible until there was 5% of the mutant in the wild-type, as shown in Fig. 2A . To improve the sensitivity, E-SSCP was performed, using the SSCP samples described above. The sensitivity of E-SSCP was improved, to 1%, as shown in Fig. 2B . On the other hand, the minimal rate of detection in mutant DNA for K-ras mutations by MASA using the PCa cell lines was 0.01%-0.001% of the total DNA as a template for PCR, as shown in a previous publication. 15 
p53 Analysis
The results of analyses of p53 and K-ras mutations in bile samples from patients with malignant diseases are summarized in Table 1 . In the samples from the 30 patients with BTCa, mutant bands of p53 were detectable in the Sup of 15 patients and in the Sed of 7 patients on conventional SSCP. The mutant bands became visible in the Sed of 3 patients only on E-SSCP, but not in the Sup. Consequently, p53 mutations were detected in the Sup of 15 patients (50.0%) and in the Sed of 10 patients (33.3%), as shown in Table 2 . Furthermore, mutant bands were observed in the Sup alone in 5 cases, with no p53-positive cases in the Sed alone. In all cases harboring the mutant in both fractions, the same pattern of changed sequence was observed. Tumor tissue in patients 7 and 17 with BTCa showed the same finding as the bile samples. The most common change was a GAEA and TAEC transition. Typical PCR-SSCP and sequence analyses are shown in Fig. 3 (patient 3 with BTCa). On examining correlation with the location of tumor, the incidence of p53 mutations was 54.5% (6/11) in proximal bile duct carcinoma, 54.5% (6/11) in distal bile duct carcinoma, and 37.5% (3/8) in gallbladder carcinoma. There was no significant difference between the incidence of p53 mutations and the different locations of BTCa. Additionally, p53 mutations were detected in 1 of 3 (33.3%) patients with malignant biliary stricture in both the Sup and Sed. On the other hand, there were no patients with cholelithiasis harboring mutant p53 (Table  2 ). These findings suggest that the p53 mutation has high specificity for cancer.
K-ras Analysis
In BTCa patients, the positive rate of K-ras mutations at codon 12 was 56.7% (17/30) in the Sup and 43.3% (13/ 30) in the Sed. Although there was no significant difference between Sup and Sed, the positive rate of K-ras mutations was higher in the former, in the same manner as that of p53. K-ras mutations were detected in the Sup alone in 8 patients and the Sed alone in 4 patients with BTCa, as listed in Table 1 , so the frequency of K-ras mutations was improved to 70.0% (21/30) by a combination assay with both Sup and Sed. On examining the incidence of K-ras mutations in relation to the location of the tumor, the incidence of K-ras mutations was 72.7% (8/11) in proximal bile duct carcinoma, 81.8% (9/11) in distal bile duct carcinoma, and 50.0% (4/8) in gallbladder carcinoma. There was no significant difference between the incidence of K-ras mutations and the locations of BTCa, as was found for p53. Analyses of the tissue samples from patients 7 and 17 with BTCa corresponded with each bile sample. The most common K-ras mutation, transition from GGT (Gly) to GAT (Asp), was found in 7 of 21 (33.3%) BTCa patients. In addition, K-ras mutations were detected in 1 of 3 
Comparison between p53 and K-ras mutations in bile from patients with BTCa
The p53 and K-ras mutations in pancreaticobiliary diseases showed concordant patterns in the different fractions of bile, as shown in Table 2 . Both p53 and K-ras mutations were positive in 12 patients and negative in 6 (patients 25-30) of the 30 patients with BTCa. Only p53 positivity was seen in 3 patients (patients 5, 10, 15), and only K-ras positivity in 9 patients (patients [16] [17] [18] [19] [20] [21] [22] [23] [24] . In 24 of the 30 patients, p53 or K-ras was positive; therefore, the rate of genetic abnormality increased to 80.0% on combination analysis of the two genes (Table 3) .
Comparison between gene analysis and cytology
A comparison between the results of gene analysis and cytologic examination, performed simultaneously in 25 patients with BTCa, is given in Fig. 4 . p53 mutations with high cancer specificity were detected in 6 of 15 (40.0%) patients in whom the bile cytologic diagnosis was negative. Notably, 2 of these patients involved p53 mutations alone (patients 5 and 15 in Table 1 ). Furthermore, in 12 of the 15 patients with negative cytology, either p53 or K-ras mutations were positive; therefore, the rate of genetic abnormality increased to 80.0% on combination analysis of both genes. In the 10 patients in the cytology-positive group, mutations of both genes were positive in 7, while there was positivity for p53 alone in 1, and K-ras positivity alone in 2. Consequently, all patients with positive cytology demonstrated either p53 or K-ras mutations, and the incidence of p53 mutations was 80.0%, with high cancer specificity.
Discussion
The incidence of p53 overexpression in BTCa tissues has been reported to range from 64% to 92%.
16-18
Although there is a discrepancy between positive immunostaining and the presence of somatic mutations, solid tumors seem to show a strong association between p53 protein overexpression and p53 gene mutation. 19 The frequency of p53 mutations has been reported to be 36%-70% [20] [21] [22] in BTCa tissues, suggesting that p53 genetic analysis is useful for the molecular diagnosis of BTCa. In the present study, p53 gene mutations were detected in 50.0% (15/30) of bile samples from BTCa patients. This incidence is no less than that in tissue samples of BTCa reported previously. Considering that the number of cancer cells dropped into the bile was very small compared with that in tissue samples, the present data indicate a sufficient sensitivity.
Some researchers have tried to analyze p53 mutations in body fluids for genetic diagnosis. Mao et al. 23 found p53 mutations in 2 of 15 sputum samples from patients with lung cancer. Sidransky et al. 24 reported that, on analyzing urine samples, p53 mutations could be detected in 11 of 15 patients with bladder cancer. We 25 also detected p53 mutations in the pancreatic juice (PJ) of 11 of 26 patients with pancreatic cancer (PCa). Although there are only two reports on the analysis of p53 mutations in bile samples for diagnosing BTCa, the sensitivity is not so high. Müller et al. 4 investigated p53 mutations in bile from patients with BTCa using temperature gradient gel electrophoresis, and obtained a positive rate of only 3.4% (1/29). Itoi et al. 5 reported the incidence of p53 mutations as 36.8% (7/19) in bile samples of BTCa examined by nested PCR-SSCP. These values are not as high as expected for the diagnosis of biliary malignancy, and when other molecular analyses or cytology are required, the amount of bile Sed may often be insufficient. Recently, Yamashita et 
Fig. 4.
Comparison between genetic analyses and cytologic examination in BTCa. ᭹, p53 and K-ras mutant; , p53 mutant only; ᭺, K-ras mutant only; ᭝, p53 and K-ras wild-type al. 6 and the authors 7 of this article found that the incidence of K-ras mutations in PCa was higher in the Sup than the Sed of PJ, suggesting that the Sup of body fluids is useful for genetic analysis. To improve the molecular diagnosis of BTCa, we analyzed gene mutations in DNA extracts not only from the Sed but also from the Sup of bile samples. In this study, the positive rate of p53 mutations was relatively high (50.0% in the Sup and 33.3% in the Sed of BTCa patients), indicating that this system is useful for improving genetic diagnosis. As we encountered only a few patients with stage I or II BTCa from whom bile samples could be obtained during this study period, it remains unknown how this method is able to contribute to the early diagnosis of BTCa. Further investigations of many patients with stage I or II BTCa will be needed to clarify its significance for early diagnosis.
The reason for these favorable findings is presumed to be as follows: spontaneous apoptosis has been reported to occur more frequently in various cancer cells than in normal cells, [26] [27] [28] [29] and small fragments of DNA from cancer cells induced by apoptosis which often harbor the mutant may easily shift to the Sup after centrifugation compared with DNA from normal epithelial cells. Therefore, the proportion of mutant to total DNA in the Sup of bile might be higher than that in the Sed of bile. This condition in Sup is considered to facilitate the efficacy of the PCR method.
In this study, no mutations of p53 were seen in either the Sup or Sed of any bile samples from 20 patients with cholelithiasis, which is consistent with previous studies to date. Kim et al. 22 reported that p53 mutations were not detected in any tissue samples from 5 patients with dysplasias and 3 patients with adenomas. Findings for p53 mutations were also negative in tissue and bile samples from 4 patients with adenomyomatosis of the gallbladder and 5 patients with cholecystitis. 5 Thus, p53 mutations of bile are considered to be highly specific for BTCa.
Because the difficulty in obtaining biopsy specimens from patients with BTCa is an obstacle to early and differential diagnosis, bile cytological examination has been used in attempts to diagnose BTCa. However, due to cell injury and degradation induced by various proteases present in the bile juice, the accuracy of cytology for the diagnosis of BTCa has not been satisfactory. 2, 3 In this series, we detected p53 mutations in 50% of bile samples from BTCa patients, but no p53 mutations were detected in the samples from patients with benign biliary diseases. Furthermore, p53 mutations, with high cancer specificity, were detected in 6 of 15 (40%) BTCa patients in whom bile cytologic diagnosis was negative, and 2 of these patients demonstrated p53 mutations alone. In addition, p53 mutations were detected in 8 of 10 cytology-positive patients (80%) with BTCa. The data suggest that the genetic analysis of p53 could considerably complement cytology.
Recently, Argani et al. 8 reported that abnormalities in p53 overexpression were more frequent in distal bile duct carcinoma than in proximal bile duct carcinoma. However, the positivity for p53 mutations had no significant correlation with the location of BTCa in our present study.
With regard to radioisotopic E-SSCP, Marchetti et al. 13 reported that serially diluted DNA samples containing gene mutations demonstrated a detection level of 1 mutant/10 6 normal alleles. However, in the present study, the sensitivity of nonradioactive E-SSCP was not increased as much as expected in the comparison between conventional SSCP and E-SSCP, using cell lines. In practice, although E-SSCP was tried in the samples of all patients in whom the mutant bands of p53 were not visible on conventional SSCP, the mutant bands became positive in the Sed of bile from three patients only on E-SSCP. However, they were detected by conventional SSCP in the Sup from these three patients, as shown in Table 1 , suggesting that E-SSCP is not so efficient. On the other hand, in some cases, in which mutant bands were visible indistinctly on conventional SSCP, it was possible for them to become clearer by E-SSCP.
It is important to discuss the significance of analyzing p53 mutations in relation to the detection of K-ras mutations in bile samples, which has been already applied to the genetic diagnosis of BTCa. The incidence of Kras mutations in bile has been reported to range from 53% to 79%, 5, 30, 31 suggesting that K-ras mutation is a promising potential marker of BTCa. However, Ajiki et al. 32 reported that K-ras codon 12 mutations were detected in 73% (8 of 11) of gallbladder dysplasias in patients with gallstone. Tanno et al. 33 found K-ras mutations in 22% (2 of 9) of high-grade hyperplasias in patients with anomalous pancreaticobiliary ductal union. Moreover, K-ras mutations have been detected in 14% (4/28) of bile samples from patients with choledocholithiasis by PCR-restriction fragment length polymorphism (RFLP), 4 and in 30% (17/56) of bile fluid samples from patients with primary sclerosing cholangitis by enriched PCR-RFLP. 34 Therefore, false-positive results for K-ras mutations in bile have become a serious problem. However, in the present study, K-ras mutations were not detected in the Sup in patients with cholelithiasis, although they were found in the Sed in 20.0% (4/ 20) of these patients, suggesting the existence of highgrade hyperplasia or dysplasia somewhere in the biliary system. Because noncancerous cells are not apt to undergo apoptosis compared with cancer cells, small fragments of DNA in bile released by apoptosis may be scarce. Furthermore, exfoliated noncancerous cells, such as hyperplastic or dysplastic cells in bile which sometimes might harbor K-ras mutations, are liable to shift to the Sed after centrifugation. These conditions may explain why the false-positive incidence of K-ras mutations in the Sup is lower than that in the Sed in bile. Further investigations will be needed to clarify this point.
K-ras mutations were detected in 70.0% (21/30) of bile samples from BTCa patients by a combination assay with both Sup and Sed, using MASA with high sensitivity in this study. When a combination assay with both genes was used, the positive rate improved to 80.0%, including three cases in which p53 alone was positive and nine cases in which K-ras alone was positive. In addition, either p53 or K-ras mutations were detected in the samples of 12 of 15 (80.0%) BTCa patients in whom bile cytologic diagnoses were negative. These findings illustrate that some patients exhibit p53 mutations without K-ras mutations, and simultaneous analyses of p53 and K-ras mutations are useful for enhancing the molecular diagnosis of BTCa.
With respect to the prevalence of mutant types of Kras detected by MASA in bile from patients with BTCa, the most common transition, from GGT (Gly) to GAT (Asp), was found in 7 of 21 (33.3%) BTCa patients in this study. Several previous studies on the mutant types of K-ras in the tissue of BTCa patients showed that the most common transition, from GGT to GAT (Asp), was found in 5 of 6 patients (83%), 35 AGT (Ser) was found in 8 of 9 patients (89%), 36 and GTT (Val) was found in 2 of 4 patients (50%). 33 The varying prevalences of the mutant types of K-ras were observed in BTCa tissues.
In conclusion, the sensitivity of detection of p53 mutations with high cancer specificity was relatively high in bile samples of BTCa. Genetic analysis of p53 could complement bile cytology. Moreover, the use of bile Sup is a novel and promising method that allows for the simultaneous analyses of alterations in the p53 and K-ras genes, after removal of the Sed for cytologic examination. Simultaneous analyses of p53 and K-ras mutations in the two fractions of bile could enhance the genetic diagnosis of BTCa.
